Last updated 18:35:02
HK$70.00
+274.73%
Phillip grey
- Listing price
- HK$18.68
- Open
- —
- High
- —
- Low
- —
- Bid / Ask
- — / —
- Volume
- —
Turnover —View source
INNOGEN-B
0259118AListed醫療健康 · 公司是一家专注于糖尿病及代谢疾病创新疗法研发、生产和商业化的生物制药企业。
INNOGEN-B (銀諾醫藥－Ｂ) (02591) is a listed Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.
- Offer price
- HK$18.68
- Final offer price
- HK$18.68
- One-lot win rate
- 0.5%
- Proceeds
- HK$682.9M
- Public oversub.
- 5341.7x
Predicted 1.4%
Lot / entry fee 200 shares · HK$4K · Sponsor CITIC Securities / CICC
- Offer starts Aug 7
- /Offer closes Aug 12
- /Grey market Aug 14
- /Listing Aug 15Now
SubscriptionINNOGEN-B: subscription-stage reference
The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.
Earlier stage- Reference rating
- Neutral
- Reference score
- 65.6
- Forecast grey range
- 0.0% – +174.2%
Pre-greyINNOGEN-B: pre-grey-market reference
The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.
Earlier stage- Reference rating
- Neutral
- Reference score
- 72.9
- Forecast grey range
- 0.0% – +175.8%
Post-greyINNOGEN-B: post-grey-market reference
The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.
Current- Reference rating
- High attention
- Reference score
- 77.8
- Forecast first-day range
- +253.8% – +338.0%
View factors and research
Model forecastListing-day trendPositiveUp probability 76.0%
Published outcome check
First-day resultBig up+206.5%
Our call: Trend call valid
Covered 15/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Good qualityCornerstone lockup
Low supportPost-lockup offer value
Medium scarcityRecent same-rule trend
—Recent same-type trend
—Recent sector trend
—Valuation
Weak appealFundamental quality
Average qualityGrowth quality
—Profitability
Weak qualityCash runway
Weak qualityCustomer concentration
—Cornerstone quality
Strong supportSponsor record
Strong recordGreenshoe arrangementGreenshoe: yes · 15%
Average supportStabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
High heatInternational placing
High heatFinal pricing position
—Actual greenshoe use
—Grey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
Post-greyThe analysis report for this IPO is being generated.
INNOGEN-B: grey-market trend
INNOGEN-B: predicted allotment
Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.
- 1 lot
- 1.4%
- A tail · Apply 1,000 lots
- 0.15 lots
- B head · Apply 1,500 lots
- 0.22 lots
- Top hammer
- 0.71 lots
Official 0.5%
Official 0.22 lots
Official 0.3 lots
Official 0.66 lots
Most likely allotment pattern：Larger Pool A applications get less extra allotment；Pool B allotment declines gradually with sizeView full allotment-odds research
How to read this page
These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.
What is the one-lot allotment rate for INNOGEN-B?
Public allotment filings put the official one-lot rate at 0.5%, versus this site's pre-allotment model estimate of 1.4%. It is an observation for a 1-lot application, not a guaranteed result.
What is the difference between A-tail and B-head for INNOGEN-B?
Based on the prospectus's legal application tiers, A-tail is 1,000 lots and B-head is 1,500 lots, representing about HK$3.7M and HK$5.6M of application principal. Official average allotment was 0.22 lots and 0.3 lots, versus pre-allotment model estimates of 0.15 lots and 0.22 lots. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.
Can the grey-market price of INNOGEN-B be treated as the listing price?
The compiled grey-market observation is about +274.7%, versus +206.5% on the listing day. Grey-market prints are pre-listing sentiment from public sources, not the official opening price.
Why does INNOGEN-B have three reference ratings?
The current status is "Listed", so start with the post-grey section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.